Dermira gains on DRM01 acne data
Dermira Inc. (NASDAQ:DERM) gained $4.23 (17%) to $28.69 on Tuesday after it said the highest dose of topical DRM01 given twice daily met all three co-primary endpoints vs. vehicle in a 420-patient Phase IIb study to treat moderate to severe facial acne vulgaris. Dermira plans to start a Phase III trial next half of the topical prodrug of an acetyl-Coenzyme A carboxylase ( ACAC; ACC) inhibitor.
The twice-daily dose of a 7.5% formulation of DRM01 significantly reduced inflammatory lesion counts from baseline to week 12 vs. vehicle (15 vs. 10.7 lesions, p=0.001), and the number of non-inflammatory lesions (17.5 vs. 9.3, p<0.001). High-dose DRM01 significantly increased the proportion of patients who improved by at least two points on the five-point Investigator's Global Assessment (IGA) score at week 12 vs. vehicle (25.9% vs. 9.8%, p=0.004). ...